Syndax Pharmaceuticals Inc (SNDX) — 10-Q Filings
All 10-Q filings from Syndax Pharmaceuticals Inc. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
Syndax Revenue Soars on New Products, Losses Persist
— Nov 3, 2025 Risk: high
Syndax Pharmaceuticals Inc. reported a significant increase in total revenues to $103.624 million for the nine months ended September 30, 2025, up from $16.000 -
Syndax Q2 Loss Widens to $60.2M Amid Rising SG&A
— Aug 4, 2025 Risk: high
Syndax Pharmaceuticals Inc. reported a net loss of $60.2 million for the three months ended June 30, 2025, compared to a net loss of $55.1 million for the same -
Syndax Pharmaceuticals Files Q1 2025 10-Q
— May 5, 2025 Risk: medium
Syndax Pharmaceuticals Inc. filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates, including inf -
Syndax Pharma Files Q3 2024 10-Q, Cites Bayer & Allergan Deals
— Nov 5, 2024 Risk: medium
Syndax Pharmaceuticals Inc. filed a 10-Q for the period ending September 30, 2024. The company reported research and development expenses for the nine months en -
Syndax Pharmaceuticals Inc. Files 10-Q for Period Ending March 31, 2024
— May 8, 2024 Risk: medium
Syndax Pharmaceuticals Inc (SNDX) filed a Quarterly Report (10-Q) with the SEC on May 8, 2024. Syndax Pharmaceuticals Inc. filed a 10-Q report for the period en
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX